Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Medical Sciences Business Development & Partnering Team are delighted to announce that the AIMday in Advanced Therapies & Regenerative Medicine is now open for registration by academics.

Are you an academic interested in finding out how your knowledge can be used to solve industry challenges? Would you like to widen your network? Meet potential collaborators / future employees? Gain insights into relevant funding schemes? 

If you answer YES to any of the above, now is the time to register for the AIMday in Advanced Therapies & Regenerative Medicine, taking place on Wednesday 3 April at the Blavatnik School of Government. A range of companies including LIft Biosciences, Alcyomics, Oxford MEStar, Novo Nordisk, DJS Antibodies, The Electrospinning Company and Bio-Techne are registered to attend, and it will be a fantastic opportunity for researchers looking to network with industry and discuss relevant questions. To see the questions posed by these companies, please visit aimday.se/atrm-2019/questions-listing.

This years AIMday follows on from previous successful AIMdays in Ageing (2016), Microscopy (2017) and Biomedical Imaging (2018).

FREE registration for academics is now open and closes on 15 March. 

Please note, advance registration is essential

To register and find out more, please visit aimday.se/ATRM-2019

What are AIMdays?

  • AIMdays provide a platform for companies to host roundtable discussions with a group of self-selecting academics
  • Industry sets the agenda and topics for discussion
  • Academics from across multiple disciplines sign up to participate in the discussions

How does it work?

Step 1: Companies submit a question/s around the theme of the day

Step 2: Oxford’s researchers sign up to answer one or more of the questions

Step 3: One question, one hour for discussion, one group of experts

 

For additional information please contact amira.burshan@medsci.ox.ac.uk

Find out more about the work of the Business Development & Partnering Team

Similar stories

Five ways the pandemic has affected routine medical care

Since the beginning of the pandemic, COVID has infected at least a third of the UK population and is estimated to have factored in the deaths of almost 200,000 people in the UK. But critically, COVID has also had a devastating impact on our healthcare systems. While this was expected, new evidence is beginning to reveal the scope of the issue – in particular the effects for people living with long-term health conditions.

Clinical trials for a malaria vaccine start in Mali and Indonesia

Sanaria Inc. announced that two new Phase 2 trials of its pioneering malaria vaccines have started. The first is in 6- to 10-year-old children living in Bancoumana, Mali, a malarious region of West Africa. The second is in Indonesian soldiers based in Sumatra, Indonesia. The soldiers will be deploying for six to nine months this coming August to an intensely malarious district in eastern Indonesia.

Mechanism of expanding bacteria revealed

A new study published in Nature has identified a potential Achilles heel in the protective layers surrounding Gram-negative bacteria that could aid in the development of next-generation antibiotics.

Oxford to receive £7 million to turn bright ideas into global opportunities

The University of Oxford has been awarded more than £7 million, the highest amount of funding given to organisations across the UK, in the latest round of UK Research and Innovation’s (UKRI) Impact Acceleration Account (IAA) funding - aimed at fueling the best, brightest and most disruptive ideas from Uk research institutions.

Discovery of gene involved in chronic pain creates new treatment target

Oxford researchers have discovered a gene that regulates pain sensitisation by amplifying pain signals within the spinal cord, helping them to understand an important mechanism underlying chronic pain in humans and providing a new treatment target.

Oxford's largest ever study into Varicose veins shows need for surgery is linked to genetics

A new international study by Oxford researchers published in Nature Communications establishes for the first time, a critical genetic risk score to predict the likelihood of patients suffering with Varicose veins to require surgery, as well as pointing the way towards potential new therapies.